Pia Weikop

Pia Weikop

Auto-generated profile, based on publicly available information

Pia Weikop

Center for Translational Neuroscience, University of Copenhagen

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2023 in Nature
Verified
Journal Article
Closed access
PDF file
RHRashad Hussain
Rashad Hussain
JTJeffrey Tithof
Jeffrey Tithof
WWWei Wang
Wei Wang
ACArokoruba Cheetham-West
Arokoruba Cheetham-West
WSWei Song
Wei Song
MNMaiken Nedergaard
Maiken Nedergaard

1 October 2015 in Physiology & Behavior
Verified
Journal Article
Closed access
GSGunnar Sørensen
Gunnar Sørensen
IRIndia A. Reddy
India A. Reddy
PWPia Weikop
Pia Weikop
DGDevon L. Graham
Devon L. Graham
GSGregg D. Stanwood
Gregg D. Stanwood
AFAnders Fink-Jensen
Anders Fink-Jensen

20 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
PPPer Plenge
Per Plenge
AAAra M. Abramyan
Ara M. Abramyan
GSGunnar Sørensen
Gunnar Sørensen
AMArne Mørk
Arne Mørk
PWPia Weikop
Pia Weikop
CLClaus Juul Loland
Claus Juul Loland
The serotonin transporter (SERT) terminates serotonin signaling by rapid presynaptic reuptake. SERT activity is modulated by antidepressants, e.g., S-citalopram and imipramine, to alleviate symptoms of depression and anxiety. SERT crystal structures reveal two S-citalopram binding pockets in the central binding (S1) site and the extracellular vestibule (S2 site). In this study, our combined in vitro and in silico analysis indicates that the bound S-citalopram or imipramine in S1 is allosterically coupled to the ligand binding to S2 through altering protein conformations. Remarkably, SERT inhibitor Lu AF60097, the first high-affinity S2-ligand reported and characterized here, allosterically couples the ligand binding to S1 through a similar mechanism. The SERT inhibition by Lu AF60097 is demonstrated by the potentiated imipramine binding and increased hippocampal serotonin level in rats. Together, we reveal a S1-S2 coupling mechanism that will facilitate rational design of high-affinity SERT allosteric inhibitors.

6 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
QSQian Sun
Qian Sun
SPSisi Peng
Sisi Peng
QXQiwu Xu
Qiwu Xu
PWPia Weikop
Pia Weikop
RHRashad Hussain
Rashad Hussain
FDFengfei Ding
Fengfei Ding
Epileptogenesis is the process whereby the previously normally functioning brain begins to generate spontaneous, unprovoked seizures. Status epilepticus (SE), which entails a massive release of neuronal glutamate and other neuroactive substances, is one of the best-known triggers of epileptogenesis. We here asked whether pharmacologically promoting glymphatic clearance during or after SE is beneficial and able to attenuate the subsequent epileptogenesis. We induced SE in adult male mice by intrahippocampal kainic acid (KA) infusion. Acute administration of a cocktail of adrenergic receptor antagonists (propranolol, prazosin, and atipamezole: PPA), enhanced glymphatic flow and effectively reduced the severity of spontaneous seizures in the chronic phase. The PPA treatment also reduced reactive gliosis and inhibited the loss of polarized expression of AQP4 water channels in the vascular endfeet of astrocytes. Administration of PPA after cessation of SE (30 hours post KA) also effectively suppressed epileptogenesis and improved outcome. Conversely, mice with constitutively low glymphatic transport due to genetic deletion of the aquaporin 4 (AQP4) water channel showed exacerbation of KA-induced epileptogenesis. We conclude that the pharmacological modulation of glymphatic fluid transport may represent a potential strategy to dampen epileptogenesis and the occurrence of spontaneous seizures following KA-induced SE.

3 January 2017 in Cerebral Cortex
Verified
Journal Article
Open access
PDF file
TBTenna Bering
Tenna Bering
MCMikkel Bloss Carstensen
Mikkel Bloss Carstensen
GWGitta Wörtwein
Gitta Wörtwein
PWPia Weikop
Pia Weikop
MRMartin Fredensborg Rath
Martin Fredensborg Rath
A molecular circadian oscillator resides in neurons of the cerebral cortex, but its role is unknown. Using the Cre-LoxP method, we have here abolished the core clock gene Arntl in those neurons. This mouse represents the first model carrying a deletion of a circadian clock component specifically in an extrahypothalamic cell type of the brain. Molecular analyses of clock gene expression in the cerebral cortex of the Arntl conditional knockout mouse revealed disrupted circadian expression profiles, whereas clock gene expression in the suprachiasmatic nucleus was still rhythmic, thus showing that Arntl is required for normal function of the cortical circadian oscillator. Daily rhythms in running activity and temperature were not influenced, whereas the resynchronization response to experimental jet-lag exhibited minor though significant differences between genotypes. The tail-suspension test revealed significantly prolonged immobility periods in the knockout mouse indicative of a depressive-like behavioral state. This phenotype was accompanied by reduced norepinephrine levels in the cerebral cortex. Our data show that Arntl is required for normal cortical clock function and further give reason to suspect that the circadian oscillator of the cerebral cortex is involved in regulating both circadian biology and mood-related behavior and biochemistry.

26 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
EKErik Kroesbergen
Erik Kroesbergen
LRLaurence V. Riesselmann
Laurence V. Riesselmann
RGRyszard S. Gomolka
Ryszard S. Gomolka
VPVirginia Plá
Virginia Plá
TETina Esmail
Tina Esmail
YMYuki Mori
Yuki Mori
We here revisited the concept that glymphatic clearance is enhanced by sleep and anesthesia. Utilizing dynamic magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), and fluorescent fiber photometry, we report brain glymphatic clearance is enhanced by both sleep and anesthesia, and sharply suppressed by wakefulness. Another key finding was that less tracer enters the brains of awake animals and that brain clearance across different brain states can only be compared after adjusting for the injected tracer dose.